Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NVIDIA
NVDA
5
Broadcom
AVGO
No Data
Express News | Eli Lilly and Co's weight loss drug has been placed under FDA review, with a decision expected by April 10, 2026.
SA Analyst Upgrades/downgrades: LLY, NVDA, AVGO, GRPN
Reported January 14, 2025: 'Eli Lilly, Novo Hit With Antitrust Suit From Drug Compounder' - Bloomberg
JPM26: Eli Lilly's Obesity Drugs Target Commercial and Governmental Access
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks
Market Chatter: Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues